Rezolute, Inc. (RZLT)

NASDAQ: RZLT · IEX Real-Time Price · USD
3.07
+0.14 (4.78%)
Aug 12, 2022 4:30 PM EDT - Market closed
4.78%
Market Cap 103.10M
Revenue (ttm) n/a
Net Income (ttm) -38.13M
Shares Out 33.58M
EPS (ttm) -3.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,761
Open 2.87
Previous Close 2.93
Day's Range 2.87 - 3.29
52-Week Range 2.26 - 11.31
Beta 2.85
Analysts Buy
Price Target 14.03 (+357.0%)
Earnings Date Sep 13, 2022

About RZLT

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema.... [Read more...]

Industry Biotechnology
Founded 2010
CEO Nevan Elam
Employees 26
Stock Exchange NASDAQ
Ticker Symbol RZLT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for RZLT stock is "Buy." The 12-month stock price forecast is 14.03, which is an increase of 357.00% from the latest price.

Price Target
$14.03
(357.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer

REDWOOD CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to d...

Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress

Announced a $130 million registered direct offering and concurrent private placement

Rezolute to Host Corporate Update Call on May 4, 2022

Company to Host Analyst and Investor Conference Call on Wednesday, May 4 at 4:30 p.m. ET Company to Host Analyst and Investor Conference Call on Wednesday, May 4 at 4:30 p.m. ET

Rezolute, Inc. Announces Closing of Registered Direct Offering

REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to di...

Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At...

REDWOOD CITY, Calif., May 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to di...

Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism

Results Presented Today at the Pediatric Endocrine Society's 2022 Annual Meeting Results Presented Today at the Pediatric Endocrine Society's 2022 Annual Meeting

RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022

Rezolute to host conference call presentation and discussion of the data on Sunday, May 1 at 2:30 p.m. ET

Rezolute Joins the Rare Disease Company Coalition

Rezolute joins group aimed at helping advance timely access to life-saving therapies for those impacted by rare diseases Rezolute joins group aimed at helping advance timely access to life-saving therap...

Rezolute (RZLT) Posts Positive Data From Congenital HI Study

Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.

Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism

The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability

Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME

Phase 2 proof-of-concept study anticipated in 2H 2022 Phase 2 proof-of-concept study anticipated in 2H 2022

Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress

Topline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end of Q1 2022 Topline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end of Q1 2022

Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress

REDWOOD CITY, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated wi...

Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent ...

REDWOOD CITY, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for me...

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Dire...

REDWOOD CITY, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for me...

Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of C...

Continuous glucose monitoring reveals undertreated hypoglycemia in patients with congenital hyperinsulinism

Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress

REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated w...

Rezolute to Participate in Upcoming Virtual Healthcare Conferences

REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to c...

Rezolute Added to Russell Microcap® Index

REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to ch...

Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs

REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated wit...

Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit

REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose imbalan...

Rezolute to Participate in Upcoming Investor Conferences in March

REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced that Nevan Charles Elam, the Company's CEO and Founder, will be presenting at the following upcomi...

Rezolute Reports Second Quarter Fiscal 2021 Financial Results

REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced its financial results for the quarter ended December 31, 2020.

Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Dia...

RZ402 is a plasma kallikrein inhibitor being investigated as a potential once-daily, oral therapy for DME